# ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

Source: https://onco.cc/trials/nct07327034/  
OnCo record `nct07327034` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ABSK-011+BSC in hepatocellular carcinoma, run by Abbisko Therapeutics Co, Ltd, now recruiting.

## Summary

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression is a phase 2 interventional study registered as NCT07327034 by Abbisko Therapeutics Co, Ltd, with 141 participants planned, started 2025-06-13 and due to reach its primary completion in 2027-06-30. Interventions recorded: ABSK-011+BSC and Placebo+BSC.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07327034
- Phase: 2
- Setting: A Randomized, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of ABSK-011 Plus Best Supportive Care (BSC) vs. Placebo Plus BSC in Previously Systemically Treated Advanced or Unresectable Hepatocellular Carcinoma Patients With FGF19 Overexpression
- Sponsor: Abbisko Therapeutics Co, Ltd
- Enrolled: 141

## Sources

- ClinicalTrials.gov NCT07327034: https://clinicaltrials.gov/study/NCT07327034

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- companies: [Abbisko Therapeutics](https://onco.cc/companies/abbisko/)

---
JSON: https://onco.cc/api/v1/entities/nct07327034.json